Strongbridge Biopharma (SBBP) Lifted to Buy at BidaskClub
Strongbridge Biopharma (NASDAQ:SBBP) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Strongbridge Biopharma in a research note on Wednesday, December 6th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Strongbridge Biopharma presently has an average rating of “Buy” and an average price target of $12.81.
Strongbridge Biopharma (NASDAQ:SBBP) traded up $0.05 during trading hours on Friday, reaching $7.40. The company had a trading volume of 239,679 shares, compared to its average volume of 369,488. The company has a market capitalization of $336.44 and a price-to-earnings ratio of -2.19. Strongbridge Biopharma has a 12 month low of $3.41 and a 12 month high of $9.02. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89.
TRADEMARK VIOLATION NOTICE: “Strongbridge Biopharma (SBBP) Lifted to Buy at BidaskClub” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/strongbridge-biopharma-sbbp-lifted-to-buy-at-bidaskclub/1904313.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.